Inhibrx, Inc. (INBX) Key Metrics
INBX valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $1.32B
- Enterprise value
- $1.53B
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 212.3
- EV / EBITDA
- 0.0
- Dividend yield
- —
- Beta
- 3.82
INBX key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsINBX valuation Price multiples at each fiscal year-end price.
INBX returns How much profit the business earns on the capital it uses.
INBX per-share figures Results divided by the shares outstanding at year-end.
INBX financial health Debt, liquidity and how easily interest is covered.
INBX efficiency & capital use Working capital cycle and where the cash goes.
INBX valuation history
INBX returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
INBX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
INBX cash returned to shareholders
INBX price vs earnings per share
INBX key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $1.22B | $222.9M | — | — | — | — | — | — | — | — |
| Enterprise value | $1.21B | $78.4M | — | — | — | — | — | — | — | — |
| P/E ratio | — | 0.1 | — | — | — | — | — | — | — | — |
| Price / sales | 941.1 | — | — | — | — | — | — | — | — | — |
| Price / book | 153.1 | 1.7 | — | — | — | — | — | — | — | — |
| EV / sales | 927.9 | 391.9 | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | 0.0 | — | — | — | — | — | — | — | — |
| Earnings yield | −11.4% | 757.0% | — | — | — | — | — | — | — | — |
| Free cash flow yield | −10.6% | −88.4% | — | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $79.00 | $15.40 | — | — | — | — | — | — | — | — |
| Per share | ||||||||||
| Revenue per share | $0.08 | $0.01 | $0.04 | $0.05 | $0.19 | $0.51 | $0.25 | $0.32 | $0.29 | $0.18 |
| Earnings per share | −$9.04 | $116.58 | −$5.12 | −$3.62 | −$2.15 | −$3.01 | −$1.41 | −$1.15 | −$0.68 | −$0.23 |
| Operating cash flow per share | −$8.38 | −$13.43 | −$4.10 | −$2.87 | −$2.11 | −$1.90 | −$0.88 | −$0.85 | −$0.65 | −$0.50 |
| Free cash flow per share | −$8.38 | −$13.61 | −$4.20 | −$2.89 | −$2.14 | −$1.95 | −$0.93 | −$0.91 | −$0.70 | −$0.50 |
| Cash per share | $8.02 | $10.54 | $5.90 | $6.83 | $3.45 | $5.09 | $0.32 | $0.08 | $0.47 | $0.55 |
| Book value per share | $0.52 | $9.23 | $0.92 | $1.45 | $1.38 | $2.99 | −$2.56 | −$2.13 | −$1.00 | −$0.25 |
| Tangible book value per share | $0.52 | $9.23 | $0.92 | $1.45 | $1.38 | $2.99 | −$2.56 | −$2.13 | −$1.00 | −$0.25 |
| Dividends per share | — | — | — | — | — | — | — | $0.03 | $0.05 | — |
| Capex per share | $0.00 | $0.18 | $0.10 | $0.02 | $0.02 | $0.05 | $0.05 | $0.05 | $0.05 | $0.01 |
| Debt per share | $6.91 | $0.56 | $4.46 | $5.16 | $1.90 | $1.48 | $1.14 | $0.35 | $0.51 | $0.52 |
| Shares outstanding | 15.5M | 14.5M | 47.1M | 40.1M | 38.0M | 25.3M | 36.6M | 27.1M | 28.8M | 36.6M |
| Change in shares outstanding | +7.0% | −69.3% | +17.5% | +5.5% | +50.5% | −30.9% | +35.0% | −5.9% | −21.2% | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −197.8% | — | −475.3% | −263.0% | −127.9% | — | — | — | — | — |
| Return on assets (ROA) | −85.6% | 690.7% | −80.6% | −65.8% | −55.6% | −89.4% | −281.9% | −228.9% | −101.0% | −38.9% |
| Return on tangible assets | −95.6% | 933.6% | −78.4% | −49.9% | −54.3% | −53.0% | −194.0% | −312.1% | −112.7% | −38.9% |
| Free cash flow margin | — | — | — | — | — | −385.2% | −372.7% | −285.3% | −239.4% | −274.8% |
| Income quality (OCF / net income) | — | −0.12 | — | — | — | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $107.0M | $8.0M | $210.1M | $207.1M | $72.1M | $37.5M | $41.7M | $9.5M | $14.7M | $18.9M |
| Cash & short-term investments | $124.2M | $152.6M | $277.9M | $273.9M | $131.3M | $128.7M | $11.5M | $2.1M | $13.5M | $20.0M |
| Net debt | −$17.2M | −$144.5M | −$67.8M | −$66.8M | −$59.2M | −$91.2M | $30.2M | $7.4M | $1.2M | −$1.1M |
| Debt / equity | 13.39 | 0.06 | 4.83 | 3.57 | 1.38 | 0.50 | — | — | — | — |
| Debt / assets | 0.73 | 0.04 | 0.68 | 0.71 | 0.48 | 0.26 | 1.58 | 0.95 | 0.85 | 0.89 |
| Net debt / EBITDA | — | −0.08 | — | — | — | — | — | — | — | — |
| Current ratio | 3.93 | 3.94 | 5.25 | 10.17 | 6.20 | 4.21 | 0.76 | 0.35 | 1.73 | 3.87 |
| Quick ratio | 3.93 | 3.94 | 5.25 | 10.18 | 6.23 | 8.33 | 0.60 | 0.21 | 1.62 | 3.87 |
| Interest coverage | -11.1 | -24.6 | -6.9 | -8.0 | -14.7 | -6.2 | -7.2 | -19.9 | -9.3 | — |
| Working capital | $99.0M | $119.7M | $239.0M | $252.9M | $116.7M | $100.8M | −$5.0M | −$10.5M | $6.5M | $15.1M |
| Invested capital | −$9.2M | −$11.0M | −$24.3M | −$8.7M | −$6.8M | −$15.7M | −$63.4M | −$50.3M | −$27.6M | −$10.4M |
| Tangible asset value | $8.0M | $133.6M | $43.5M | $58.1M | $52.4M | $75.5M | −$93.6M | −$57.6M | −$22.4M | $1.2M |
| Net current asset value | −$5.7M | $113.2M | $31.0M | $47.7M | $41.0M | $63.9M | −$104.5M | −$62.0M | −$24.2M | $375,000 |
| Graham number | — | $155.58 | — | — | — | — | — | — | — | — |
| Graham net-net per share | −$0.91 | $7.30 | $0.30 | $1.03 | $0.88 | −$0.15 | −$2.92 | −$2.36 | −$0.87 | −$0.00 |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | — | — | $828,000 | $1.4M | — |
| Share buybacks (net) | — | — | — | — | $340,000 | — | — | — | — | — |
| Capex / revenue | 2.4% | 1,298.5% | 255.2% | 31.3% | 12.1% | 10.6% | 19.9% | 16.6% | 16.0% | 3.2% |
| Capex / depreciation | 0.01 | 1.14 | 3.86 | 0.56 | 0.72 | 1.34 | 1.56 | 2.11 | 3.36 | 0.85 |
| Stock-based compensation / revenue | 856.8% | 29,259.0% | 1,380.3% | 932.9% | 211.2% | 39.2% | 43.7% | 28.9% | 14.1% | 8.3% |
| R&D / revenue | 8,694.5% | 101,871.5% | 10,591.6% | 5,026.7% | 1,002.7% | 573.8% | 526.9% | 389.2% | 304.0% | 254.9% |
| SG&A / revenue | 1,792.1% | 63,952.5% | 1,632.3% | 963.6% | 173.4% | 53.4% | 99.2% | 54.1% | 31.1% | 27.3% |
| Efficiency | ||||||||||
| Days sales outstanding | 83.8 | 1,093.2 | 104.9 | 94.5 | 38.2 | 15.0 | 22.6 | 29.4 | 30.3 | — |
| Days of inventory on hand | — | — | — | -1.9 | -8,836.9 | -313.1 | 21.0 | 18.1 | 14.3 | — |
| Days payables outstanding | 1,116.4 | 1,613.3 | 2,954.3 | 28.9 | 1,533.3 | 41.2 | 36.7 | 39.9 | 6.7 | 3.6 |
| Cash conversion cycle (days) | -1,032.6 | -520.1 | -2,849.4 | 63.7 | -10,331.9 | -339.2 | 6.9 | 7.6 | 37.8 | — |
| Receivables turnover | 4.36 | 0.33 | 3.48 | 3.86 | 9.54 | 24.33 | 16.12 | 12.40 | 12.06 | — |
| Payables turnover | 0.33 | 0.23 | 0.12 | 12.63 | 0.24 | 8.87 | 9.93 | 9.16 | 54.16 | 101.75 |
| Inventory turnover | — | — | — | — | — | — | 17.36 | 20.21 | 25.54 | — |
| Asset turnover | 0.01 | 0.00 | 0.01 | 0.01 | 0.05 | 0.15 | 0.50 | 0.63 | 0.44 | 0.31 |
| Average receivables | $298,500 | $599,000 | $517,500 | $567,500 | $746,500 | $526,500 | $564,000 | $693,000 | $696,000 | — |
| Average payables | $7.6M | $10.1M | $9.6M | $8.7M | $11.3M | $8.3M | $4.8M | $3.7M | $471,000 | $167,000 |
| Average inventory | — | — | — | −$567,500 | −$65.1M | −$63.0M | $2.8M | $1.7M | $999,000 | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from INBX's annual financial statements (latest annual report filed March 19, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
INBX valuation and financial ratios
Inhibrx earned a return on equity of −197.8% in fiscal 2025. It ended the year with $107.0 million of debt and $124.2 million in cash and short-term investments, a net cash position of $17.2 million. The share count fell 57.6% from 36.6M to 15.5M over 9 years.
See the INBX income statement, the INBX chart for price history, or the INBX stock overview for the latest quote and news.
INBX key metrics FAQ
What is Inhibrx's return on equity?
Inhibrx's return on equity (ROE) was −197.8% in fiscal 2025: net income of -$140.1 million on average shareholders' equity of $70.8 million.
How much debt does Inhibrx have?
Inhibrx had total debt of $107.0 million at the end of fiscal 2025, a debt-to-equity ratio of 13.39 and more cash than debt.
What is Inhibrx's free cash flow yield?
Inhibrx generated -$129.8 million of free cash flow in fiscal 2025, a free cash flow yield of −10.6% on its market value at year-end ($1.2 billion).
What is Inhibrx's current ratio?
Inhibrx's current ratio was 3.93 at the end of fiscal 2025: current assets were 3.93 times current liabilities.